{"id":59174,"date":"2026-03-10T16:18:16","date_gmt":"2026-03-10T08:18:16","guid":{"rendered":"https:\/\/flcube.com\/?p=59174"},"modified":"2026-03-10T16:18:18","modified_gmt":"2026-03-10T08:18:18","slug":"everest-medicines-launches-etrasimod-in-china-next-gen-s1p-modulator-hits-market-for-ulcerative-colitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59174","title":{"rendered":"Everest Medicines Launches Etrasimod in China \u2013 Next-Gen S1P Modulator Hits Market for Ulcerative Colitis"},"content":{"rendered":"\n

Everest Medicines<\/strong> (HKG: 1952<\/a>) announced the formal commercial launch of Etrasimod<\/strong>, with the first prescription issued on the same day<\/strong>, marking the China market entry<\/strong> of the next-generation sphingosine-1-phosphate (S1P) receptor modulator<\/strong>. The drug, which received NMPA approval in February 2026<\/strong> for moderately to severely active ulcerative colitis (UC)<\/strong>, represents Everest’s first commercialized asset<\/strong> from its 2017 Arena Pharmaceuticals partnership<\/strong>, positioning the company to capture share of China’s rapidly expanding inflammatory bowel disease market<\/strong>.<\/p>\n\n\n\n

Launch Milestone<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Product<\/strong><\/td>Etrasimod<\/td><\/tr>
Drug Class<\/strong><\/td>Next-generation S1P receptor modulator (S1P1,4,5)<\/td><\/tr>
Developer<\/strong><\/td>Arena Pharmaceuticals (acquired by Pfizer 2022)<\/td><\/tr>
China Rights<\/strong><\/td>Everest Medicines \u2013 exclusive development, manufacturing, commercialization in Greater China and South Korea (2017 agreement)<\/td><\/tr>
NMPA Approval<\/strong><\/td>February 2026<\/td><\/tr>
Indication<\/strong><\/td>Moderately to severely active ulcerative colitis (inadequate response\/intolerance to conventional therapy or biologics)<\/td><\/tr>
Launch Date<\/strong><\/td>9\u202fMar\u202f2026 (first prescription issued)<\/td><\/tr>
Sponsor<\/strong><\/td>Everest Medicines (HKG: 1952)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>Etrasimod Specification<\/th><\/tr><\/thead>
Target<\/strong><\/td>Sphingosine-1-phosphate receptors 1, 4, and 5 (S1P1,4,5)<\/td><\/tr>
Mechanism<\/strong><\/td>Sequesters lymphocytes in lymph nodes; reduces circulating autoreactive T-cells in gut mucosa<\/td><\/tr>
Pharmacological Design<\/strong><\/td>Optimized selectivity vs. first-gen S1P modulators<\/td><\/tr>
Route<\/strong><\/td>Oral once-daily<\/td><\/tr>
Differentiation<\/strong><\/td>No requirement for first-dose cardiac monitoring (vs. fingolimod); rapid onset; improved lymphocyte recovery profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Positioning vs. Standard of Care:<\/strong><\/p>\n\n\n\n

Parameter<\/th>Etrasimod<\/th>Conventional Therapy<\/th>Biologics (anti-TNF, vedolizumab)<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>S1P1,4,5 modulation<\/td>5-ASA, immunosuppressants<\/td>Systemic\/integrin-targeted biologics<\/td><\/tr>
Administration<\/strong><\/td>Oral, no infusion<\/td>Oral\/topical<\/td>IV\/SC injection<\/td><\/tr>
Safety Profile<\/strong><\/td>No cardiac monitoring; manageable lymphopenia<\/td>GI intolerance, nephrotoxicity<\/td>Immunosuppression, infusion reactions<\/td><\/tr>
Positioning<\/strong><\/td>Bio-na\u00efve and bio-failure patients<\/td>First-line maintenance<\/td>Moderate-severe, hospitalization risk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Commercial Strategy<\/h2>\n\n\n\n
Factor<\/th>Strategic Implication<\/th><\/tr><\/thead>
China UC Market<\/strong><\/td>400,000+ diagnosed patients; 10% annual growth; biologic penetration <15% vs. 40%+ in U.S.\/EU<\/td><\/tr>
Unmet Need<\/strong><\/td>Significant patient population with inadequate response to 5-ASA or intolerance to anti-TNF therapy<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Expected NRDL negotiation 2026-2027; premium positioning justified by oral convenience vs. biologics<\/td><\/tr>
Pfizer Synergy<\/strong><\/td>Global Arena acquisition validates etrasimod mechanism; Everest retains China commercial independence<\/td><\/tr>
Pipeline Expansion<\/strong><\/td>Crohn’s disease Phase III ongoing; atopic dermatitis, alopecia areata potential indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Competitor<\/th>Product<\/th>Mechanism<\/th>China Status<\/th>Etrasimod Advantage<\/th><\/tr><\/thead>
Novartis<\/strong><\/td>Gilenya (fingolimod)<\/td>S1P1,2,3,4,5 (non-selective)<\/td>Approved (MS)<\/td>Selectivity reduces cardiac\/bronchial adverse effects<\/td><\/tr>
BMS<\/strong><\/td>Zeposia (ozanimod)<\/td>S1P1,5<\/td>Approved (UC) in U.S.\/EU; China pending<\/td>S1P4 engagement may enhance efficacy; first-mover China advantage<\/td><\/tr>
Pfizer<\/strong><\/td>Velsipity (etrasimod)<\/td>S1P1,4,5<\/td>Approved (UC) U.S. 2023<\/td>Everest exclusive China rights; local manufacturing<\/td><\/tr>
Everest<\/strong><\/td>Etrasimod<\/strong><\/td>S1P1,4,5<\/strong><\/td>Launched (UC)<\/strong><\/td>Only next-gen S1P modulator approved in China for IBD<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward-Looking Priorities<\/h2>\n\n\n\n